早期肺癌的创新之路
①OA11.03 一项定量分析：磨玻璃阴影和实性成分的肺癌患者亚肺叶切除术后的长期预后Prognostic Impact of Ground Glass Opacity Component and Consolidation Size after Sublobar Resection: A Quantitative Analysis讲者：J.Y. Kim,Asan Medical Center②OA11.04肺癌患者进行肺段切除术前应优先评估哪些淋巴结？Which Lymph Nodes Should be Evaluated with Priority in Segmentectomy for Lung Cancer?讲者：J. Ichinose, A. Cancer Institute Hospital of JFCR③OA11.05A微创手术与立体定向放疗治疗I期NSCLC的倾向匹配比较Propensity-Matched Comparison between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage I NSCLC讲者：E. Farinelli Alma Mater Studiorum-University of Bologna④OA11.06肺段切除术 vs亚肺叶切除术治疗≤2cm高风险的NSCLCSublobar Resection vs. Lobectomy for Non-Small-Cell Lung Cancers 2cm or Less in Size with High-Risk Features讲者：A.Mathey-Andrews Massachusetts General Hospital⑤MA11.03人工智能术中诊断不明肺结节的首次人体前瞻性验证First in Human Prospective Validation of Intraoperative Artificial Intelligence Guided Diagnosis of Indeterminate Lung Nodules讲者：F.Azari，University of Pennsylvania⑥MA11.04视频辅助的AI在胸腔镜肺叶切除术中的应用：手术结构解剖和相位识别Video-Based Artificial Intelligence in Thoracoscopic Lobectomy for Lung Cancer: Surgical Structures Segmentation and Phase Recognition讲者：H. Liang，the first affiliated hospital of Guangzhou Medical University⑦MA11.05早期肺腺癌中长期存活和复发患者的生物免疫标记物的区别鉴定Identification of Bio-Immune Markers that Differentiate Long-Term Survivors from Relapse in Patients with Early-Stage Lung Adenocarcinomas讲者：Y.Lou，Mayo CLinic⑧MA11.06肿瘤激活荧光分子用于肺癌患者术中鉴别的II期试验结果Results from a Phase II trial of a Tumor-Activated Fluorescent Molecule for the Intra-Operative Identification of Lung Cancer讲者：G.M. Wright，G.M. Wright⑨MA11.08 IMpower010研究：阿替利珠单抗辅助治疗NSCLC的肿瘤突变负担和无病生存率的探索性分析IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC讲者：E. FELIP，Vall d’Hebron University Hospital⑩MA11.09 SAKK 16/18:新辅助化疗联合度伐利尤单抗、免疫调节放疗治疗III期NSCLC的术后中期分析SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC Surgical Interim Analysis.讲者：P. Dorn，Inselspital, Bern University Hospital⑪MA11.10静脉注射吲哚菁绿在肺段切除术中的应用Intravenous Indocyanine Green Administration Provides Sufficient Margins in Pulmonary Segmentectomy讲者：T. Ochi，Chiba University Graduate School of Medicine⑫MA11.11奥希替尼新辅助治疗可切除EGFR突变NSCLC的耐药持久性 (NORA研究)Drug Tolerant Persister Cells to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer Harboring EGFR Mutations (NORA)讲者：J.B.Yonsei Cancer Center, Yonsei University College of Medicine突破界限：早期NSCLC辅助治疗和新辅助治疗
①OA12.03 一项比较肺叶切除术和亚肺叶切除术治疗T1aN0 NSCLC后的第二原发性肺癌发病率分析（CALGB 140503）
An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aN0 NSCLC讲者：T.E. Stinchcombe Duke Cancer Institute②OA12.04立体定向消融放疗后联合纳武利尤单抗治疗早期NSCLC：i-SABR 随机试验Nivolumab After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial讲者：张玉蛟教授，美国MD安德森癌症中心③OA12.05 度伐利尤单抗+化疗术前新辅助治疗，以及度伐利尤单抗术后辅助治疗可切除NSCLC的手术预后结果（AEGEAN研究）Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)讲者：T.Mitsudomi，Division of Thoracic Surgery④OA12.06度伐利尤单抗+化疗新辅助治疗，随后度伐利尤单抗辅助治疗可切除EGFR突变NSCLC（AEGEAN研究）Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)讲者：J. He，中国医学科学院肿瘤医院开启可切除III期NSCLC治疗新纪元
①OA06.03 可切除III期NSCLC的国际EORTC调研An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer讲者：I.Houda，Amsterdam University Medical Centers②OA06.04可切除NSCLC术后免疫联合放化疗新辅助治疗的疗效：INCREASE试验Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial讲者：A.Dickhoff, D，Amsterdam University Medical Center③OA06.05可切除III期NSCLC共识定义：EORTC-肺癌组与其他科学学会的倡议Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies讲者：A-M. Dingemans，Erasmus MC④OA06.06：新型多参数生物标志物评估免疫新辅助治疗NSCLC的病理缓解疗效：一项真实世界研究A Novel Multiparameter Biomarker of Pathological Response for NSCLC Receiving Neoadjuvant Immunotherapy: A Real-world Study讲者：S. Wu，广东省人民医院⑤MA16.03 Tremelimumab+度伐利尤单抗后接受放化疗治疗不可切除局部晚期NSCLC的诱导试验Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial.讲者：M.M. Smeenk，Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital⑥MA16.04 ctDNA的NGS定量检测应与所用方法相适应Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used讲者：R. Serna Blasco，ospital Universitario Puerta de Hierro-Majadahonda⑦MA16.05 低剂量放疗、化疗联合度伐利尤单抗新辅助治疗潜在可切除III期NSCLC的Ib期试验Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC讲者：J. Li，Sichuan Clinical Research Center for Cancer⑧MA16.08 MR引导的大分割放疗和同步化疗治疗局部晚期NSCLC的疗效The Efficacy of MR-Guided Hypo-Fractionated Radiotherapy and Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer讲者：H. Liu，Sun Yat-sen University Cancer Center⑨MA16.09 基于CT的AI预测在NSCLC良恶性MLN的诊断价值Evaluation of the Diagnostic Performance of AI Accompanied by CT Images in the Differentiation of Malignant or Benign MLN in NSCLC讲者：Y. KAHYA，Ankara University Faculty of Medicine⑩MA16.10 II期PRoT-BM试验的5年随访结果更新An Update 5 Years of Randomized Phase 2 Study (PRoT-BM Trial)讲者：O. Arrieta，Instituto Nacional de Cancerología局部晚期NSCLC未来发展之路
①OA17.03度伐利尤单抗治疗放化疗后III期不可切除EGFR突变NSCLC的真实世界结果（PACIFIC-R研究）Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R)讲者：S. Peters，Department of Oncology, Centre Hospitalier Universitaire Vaudois②OA17.04放疗对局部晚期NSCLC的长期临床结果：NRG Oncology-RTOG 0617的5年二次分析结果Long-Term Outcomes by Radiation Technique for Locally-Advanced Non-small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years讲者：S.G. Chun， MD Anderson③OA17.05 NRG-RTOG 0617转化分析：免疫生物标志物与III期NSCLC生存率的关联Association Between Pre-Treatment Circulating Immune Biomarkers And Survival In Stage III NSCLC: A Translational Analysis From NRG-RTOG 0617讲者：M.Machtay，Penn State University Cancer Institute④OA17.06 PD-L1表达在放化疗治疗不可切除III期NSCLC的预测价值The Predictive Value of PD-L1 levels on Circulating Stromal Cells in Unresectable Stage 3 NSCLC Treated with Chemoradiation讲者：S. Lin，The University of Texas MD Anderson Cancer Center精彩资讯等你来责任编辑：Sheep
*医学界力求其发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。
